Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
7-Methylxanthine for Childhood Myopia
NCT00263471Phase 2
Key facts
- Status
- Unknown
- Start
- Oct 2003
- Sponsor
- Trier Research Laboratories
- Modality
- Small Molecules
- Drugs
- 7-methylxanthine
- Conditions
- myopia
01
Overview
Phase 2, randomised trial in myopia comparing 7-methylxanthine with Placebo (2 arms). Primary endpoint: Axial growth at 12 months. Status: unknown.
02
Design
2 arms- Study design
- Randomized
7-methylxanthine
7-methylxanthine 400 mg per day
Placebo
Placebo tablets
03
Who it enrols
Children aged 8-13 years with myopia and an axial growth rate of >= 0.15 mm/year, without severe general ailments or other eye diseases.
04
Endpoints
Primary
Axial growth
Secondary
Myopia progression
Beyond the preview
Go deeper on NCT00263471.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00263471.